id
stringlengths 1
5
| question_id
stringlengths 1
5
| document_id
stringlengths 5
7
| question
stringlengths 55
970
| type
stringclasses 1
value | choices
list | context
stringlengths 0
971
| answer
sequence |
|---|---|---|---|---|---|---|---|
0 | 150 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Incidence of minor hypoglycaemia? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
1 | 191 | 2517154 | Compared to Placebo what was the result of Infliximab on Dysmenorrhea scores? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"no significant difference"
] |
2 | 113 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
3 | 95 | 2944158 | Compared to routine replacement what was the result of staff inclination replacement on IVD dwell times? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001). | [
"significantly increased"
] |
4 | 163 | 2708184 | Compared to Body-weight supported treadmill training combined with Lokomat (Pre-test) what was the result of Body-weight supported treadmill training combined with Lokomat (Post-test) on Berg Balance Scale score? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved) | [
"significantly increased"
] |
5 | 140 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (all doses) plus glimepiride on HOMA-IR? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
6 | 106 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (0.6 mg) plus glimepiride on HbA1c level at 26 weeks? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
7 | 169 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Parasite clearance at day 2? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"no significant difference"
] |
8 | 162 | 2708184 | Compared to Body-weight supported treadmill training combined with Lokomat (Pre-test) what was the result of Body-weight supported treadmill training combined with Lokomat (Post-test) on Physical performance battery scores? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved) | [
"significantly increased"
] |
9 | 142 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Reductions in systolic blood pressure? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
10 | 178 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Parasitaemias associated with gametocytaemia? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"no significant difference"
] |
11 | 149 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Pulse variations? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
12 | 196 | 3187863 | Compared to Normal unit & Special unit what was the result of Midwife-led unit on Pain relief: Epidural anesthesia? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13). | [
"significantly decreased"
] |
13 | 148 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Pulse variations? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
14 | 152 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Incidence of minor hypoglycaemia? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
15 | 92 | 2944158 | Compared to staff inclination replacement what was the result of routine replacement on phlebitis? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001). | [
"no significant difference"
] |
16 | 154 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (all doses) plus glimepiride on Changes in calcitonin at week 26? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
17 | 125 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Postprandial plasma glucose? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
18 | 121 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
19 | 207 | 4106715 | Compared to placebo group what was the result of recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) on attain 8 weeks continuous abstinence from weeks 19 through 26? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | 3'AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37). | [
"significantly increased"
] |
20 | 124 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (0.6 mg) plus glimepiride on Postprandial plasma glucose? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
21 | 157 | 2708184 | Compared to Slow treadmill speed what was the result of Fast treadmill speed on Locomotor-training effects? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved) | [
"no significant difference"
] |
22 | 107 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on HbA1c level at 26 weeks? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
23 | 170 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Recurrent infections at day 56? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"significantly decreased"
] |
24 | 173 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Baseline white blood cell count? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"significantly increased"
] |
25 | 156 | 2708184 | Compared to Manually-assisted body-weight supported treadmill training what was the result of Body-weight supported treadmill training combined with Lokomat on Paretic step length ratio? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved) | [
"no significant difference"
] |
26 | 171 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Superiority of treatment given by survival curves? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"significantly increased"
] |
27 | 176 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Headache? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"significantly decreased"
] |
28 | 91 | 2944158 | Compared to staff inclination replacement what was the result of routine replacement on IVD complications per person? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001). | [
"no significant difference"
] |
29 | 90 | 2944158 | Compared to staff inclination replacement what was the result of routine replacement on cost per patient? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001). | [
"significantly increased"
] |
30 | 105 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on HbA1c level at 26 weeks? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
31 | 187 | 2517154 | Compared to Placebo what was the result of Infliximab on Bleeding during surgery? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"no significant difference"
] |
32 | 133 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Proinsulin : insulin ratio? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
33 | 103 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Postprandial plasma glucose? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
34 | 158 | 2708184 | Compared to Body-weight supported treadmill training combined with Lokomat (Pre-test) what was the result of Body-weight supported treadmill training combined with Lokomat (Post-test) on Self-selected overground walk velocity? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved) | [
"significantly increased"
] |
35 | 174 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Fever resolution by day 1? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"significantly increased"
] |
36 | 179 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Pruritus? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"significantly decreased"
] |
37 | 126 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (0.6 mg) plus glimepiride on ADA postprandial plasma glucose goals less than 10.0 mmol/l? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
38 | 118 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (0.6 mg) plus glimepiride on ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
39 | 132 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Proinsulin : insulin ratio? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
40 | 194 | 3187863 | Compared to Normal unit & Special unit what was the result of Midwife-led unit on Labour dystocia? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13). | [
"significantly decreased"
] |
41 | 190 | 2517154 | Compared to Placebo what was the result of Infliximab on Pain killers intake? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"significantly increased"
] |
42 | 122 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
43 | 198 | 3187863 | Compared to Normal unit & Special unit what was the result of Midwife-led unit on Postpartum haemorrhage? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13). | [
"no significant difference"
] |
44 | 172 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Serious adverse events? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"no significant difference"
] |
45 | 167 | 3001156 | Compared to Comparison arm what was the result of Promotion by CHWs of maternal and newborn-care interventions on Care-seeking from unqualified providers (such as village doctors) for ill newborns ? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | the proportion of families who sought care from unqualified providers, such as unlicensed village doctors, remained unchanged in the comparison arm, but declined significantly in the intervention arm | [
"significantly decreased"
] |
46 | 202 | 4106715 | Compared to placebo what was the result of high Ab group on Prolonged abstinence from smoking rates to 6 months? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | 3'AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37). | [
"significantly increased"
] |
47 | 201 | 2688140 | Compared to table-based PEEP (control) group what was the result of Decremental PEEP titration group on The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents did not differ between the groups (Table 2). | [
"no significant difference"
] |
48 | 141 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Reductions in systolic blood pressure? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
49 | 181 | 2517154 | Compared to Placebo what was the result of Infliximab on Severity of pain? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"no significant difference"
] |
50 | 151 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Incidence of minor hypoglycaemia? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
51 | 112 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
52 | 153 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (all doses) plus glimepiride on Changes in calcitonin at week 26? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
53 | 102 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Fasting plasma glucose at week 26? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
54 | 129 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (all doses) plus glimepiride on ADA postprandial plasma glucose goals less than 10.0 mmol/l? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
55 | 195 | 3187863 | Compared to Normal unit & Special unit what was the result of Midwife-led unit on Oxytocin infusion for augmentation of labour? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13). | [
"significantly decreased"
] |
56 | 104 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Postprandial plasma glucose? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
57 | 206 | 4106715 | Compared to non-abstainers in the placebo group what was the result of non-abstainers (weeks 19–52) with high Ab levels on Reduction of daily cigarette consumption and cotinine? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | 3'AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37). | [
"significantly increased"
] |
58 | 116 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (0.6 mg) plus glimepiride on Fasting plasma glucose at week 26? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
59 | 168 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Parasite clearance at day 1? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"significantly increased"
] |
60 | 136 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on HOMA-B? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
61 | 182 | 2517154 | Compared to Placebo what was the result of Infliximab on Nodules diameters? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"no significant difference"
] |
62 | 165 | 3001156 | Compared to Comparison arm what was the result of Promotion by CHWs of maternal and newborn-care interventions on Care-seeking from qualified providers for ill newborns ? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | the proportion of families who sought care from unqualified providers, such as unlicensed village doctors, remained unchanged in the comparison arm, but declined significantly in the intervention arm | [
"significantly increased"
] |
63 | 197 | 3187863 | Compared to Normal unit & Special unit what was the result of Midwife-led unit on Pain relief: Acupuncture? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13). | [
"significantly increased"
] |
64 | 161 | 2708184 | Compared to Body-weight supported treadmill training combined with Lokomat (Pre-test) what was the result of Body-weight supported treadmill training combined with Lokomat (Post-test) on Improvement in lower extremity Fugl-Meyer score ? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved) | [
"significantly increased"
] |
65 | 184 | 2517154 | Compared to Placebo what was the result of Infliximab on Extend of the disease as visualized during surgery? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"no significant difference"
] |
66 | 200 | 2688140 | Compared to table-based PEEP (control) group what was the result of Decremental PEEP titration group on The survival rate / overall mortality of patients with ARDS? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents did not differ between the groups (Table 2). | [
"no significant difference"
] |
67 | 123 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Postprandial plasma glucose? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
68 | 180 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Haemoglobin concentration? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"no significant difference"
] |
69 | 203 | 4106715 | Compared to placebo what was the result of low Ab group on Prolonged abstinence from smoking rates to 6 months? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | 3'AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37). | [
"no significant difference"
] |
70 | 135 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on HOMA-B? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
71 | 139 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (all doses) plus glimepiride on HOMA-IR? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
72 | 183 | 2517154 | Compared to Placebo what was the result of Infliximab on Endometrial thickness? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"no significant difference"
] |
73 | 101 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Fasting plasma glucose at week 26? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
74 | 94 | 2944158 | Compared to staff inclination replacement what was the result of routine replacement on occlusion? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001). | [
"no significant difference"
] |
75 | 99 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on HbA1c level at 26 weeks? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
76 | 144 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Reductions in systolic blood pressure? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
77 | 189 | 2517154 | Compared to Placebo what was the result of Infliximab on Pain estimates after surgery? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"no significant difference"
] |
78 | 160 | 2708184 | Compared to Body-weight supported treadmill training combined with Lokomat (Pre-test) what was the result of Body-weight supported treadmill training combined with Lokomat (Post-test) on Late Life Function and Disability Instrument? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved) | [
"no significant difference"
] |
79 | 145 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (all doses) plus glimepiride on Decreases in diastolic blood pressure? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
80 | 147 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (all doses) plus glimepiride on Pulse variations? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
81 | 155 | 2708184 | Compared to Manually-assisted body-weight supported treadmill training what was the result of Body-weight supported treadmill training combined with Lokomat on Self-selected overground walk velocity? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved) | [
"no significant difference"
] |
82 | 117 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Fasting plasma glucose at week 26? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
83 | 143 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Reductions in systolic blood pressure? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
84 | 166 | 3001156 | Compared to Comparison arm what was the result of Promotion by CHWs of maternal and newborn-care interventions on Care-seeking from the Kumudini Hospital for ill newborns ? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | the proportion of families who sought care from unqualified providers, such as unlicensed village doctors, remained unchanged in the comparison arm, but declined significantly in the intervention arm | [
"significantly increased"
] |
85 | 111 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
86 | 137 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on HOMA-B? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
87 | 114 | 2871176 | Compared to Liraglutide (1.2 mg) plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Patients reaching HbA1c goals less than 7.0% ? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
88 | 108 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (0.6 mg) plus glimepiride on HbA1c level at 26 weeks? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"no significant difference"
] |
89 | 128 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on ADA postprandial plasma glucose goals less than 10.0 mmol/l? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
90 | 193 | 3187863 | Compared to Normal unit & Special unit what was the result of Special unit on Perineal outcome: the number of episiotomies or the incidence of sphincter injuries? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13). | [
"no significant difference"
] |
91 | 159 | 2708184 | Compared to Body-weight supported treadmill training combined with Lokomat (Pre-test) what was the result of Body-weight supported treadmill training combined with Lokomat (Post-test) on 6-minute walk test? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved) | [
"no significant difference"
] |
92 | 188 | 2517154 | Compared to Placebo what was the result of Infliximab on Tissue examination by routine pathology? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"no significant difference"
] |
93 | 134 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Proinsulin : insulin ratio? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
94 | 177 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Cure rate at day 28? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"no significant difference"
] |
95 | 185 | 2517154 | Compared to Placebo what was the result of Infliximab on Macroscopic aspect of the tissue? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). | [
"no significant difference"
] |
96 | 175 | 2864284 | Compared to Chloroquine what was the result of Dihydroartemisinin-piperaquine on Fever resolution by day 2? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59). | [
"no significant difference"
] |
97 | 115 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.8 mg) plus glimepiride on Fasting plasma glucose at week 26? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
98 | 127 | 2871176 | Compared to Placebo plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on ADA postprandial plasma glucose goals less than 10.0 mmol/l? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly increased"
] |
99 | 131 | 2871176 | Compared to Rosiglitazone plus glimepiride what was the result of Liraglutide (1.2 mg) plus glimepiride on Proinsulin : insulin ratio? | multiple_choice | [
"significantly increased",
"no significant difference",
"significantly decreased"
] | The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values. | [
"significantly decreased"
] |
End of preview. Expand
in Dataset Viewer.
Dataset Card for Evidence Inference 2.0
The dataset consists of biomedical articles describing randomized control trials (RCTs) that compare multiple treatments. Each of these articles will have multiple questions, or 'prompts' associated with them. These prompts will ask about the relationship between an intervention and comparator with respect to an outcome, as reported in the trial. For example, a prompt may ask about the reported effects of aspirin as compared to placebo on the duration of headaches. For the sake of this task, we assume that a particular article will report that the intervention of interest either significantly increased, significantly decreased or had significant effect on the outcome, relative to the comparator.
Citation Information
@inproceedings{deyoung-etal-2020-evidence,
title = "Evidence Inference 2.0: More Data, Better Models",
author = "DeYoung, Jay and
Lehman, Eric and
Nye, Benjamin and
Marshall, Iain and
Wallace, Byron C.",
booktitle = "Proceedings of the 19th SIGBioMed Workshop on Biomedical Language Processing",
month = jul,
year = "2020",
address = "Online",
publisher = "Association for Computational Linguistics",
url = "https://www.aclweb.org/anthology/2020.bionlp-1.13",
pages = "123--132",
}
- Downloads last month
- 76